Risk Management & Treatment

Biomarkers used for treatment selection

The following tumor biomarkers may be used to select treatment for the cancer types listed below. Speak with your doctor about other tests and treatments, which may be available. 

Cancer Treatment/s
  Breast Colorectal Endometrial Melanoma Ovarian Pancreatic

 

BRAFV600E   X   X      

Braftovi (encorafenib)
Braftovi in combination with Mektovi (binimetinib)
Cotellic (cobimetinib)
Zelboraf (vemurafenib) 

,           X   X Lynparza (olaparib) 
Rubraca ()
Zejula® ()
Epidermal growth factor
receptor (EGFR) mutation testing
  X          

Erbitux (cetuximab)
Vectibix (panitumumab) 

Estrogen/Progesterone receptor
(ER/PR) expression
X   X        

Aromatase inhibitors (AIs)
Tamoxifen
Raloxifene

Her2neu overexpression X X X         Herceptin (trastuzumab)
Perjeta (pertuzumab)
Tuksya (tucatinib)
Kadcyla (ado-trastuzumab emtansine) 

Deficiency ()
        X    

Lynparza (olaparib) 
Zejula® ()

Response (HRR) pathway mutations (, , , , , CDK12, , FANCL, , RAD51B, , RAD54)             X Lynparza (olaparib) 
KRAS mutation   X          

Erbitux (cetuximab)
Vectibix (panitumumab) 

MSI-H () or dMMR/MMR-D (Mismatch Repair Deficient) X X X X X X X Keytruda (pembrolizumab)
MSI-H () or dMMR/MMR-D (Mismatch Repair Deficient)   X           Opdivo (nivolumab) 
Yervoy (ipilimumab)
dMMR/MMR-D (Mismatch Repair Deficient)     X         Jemperli (dostarlimab)
NTRK fusion X X X X X X X Vitrakvi (larotrectinib)
PDL1 expression X             Tecentriq (atezolizumab)
PIK3CA X             Piqray (alpelisib),
(TMB) X X X X X X X Keytruda (pembrolizumab)
Last updated January 22, 2022